Qiagen (NYSE:QGEN) Lowered to “Reduce” at Kepler Capital Markets

Kepler Capital Markets downgraded shares of Qiagen (NYSE:QGEN) from a hold rating to a reduce rating in a research report released on Wednesday morning, BenzingaRatingsTable reports.

Several other equities research analysts have also recently weighed in on the company. Piper Jaffray Companies dropped their target price on Qiagen from $36.00 to $31.00 and set a neutral rating for the company in a report on Tuesday. DZ Bank restated a neutral rating on shares of Qiagen in a report on Wednesday, July 24th. Bank of America dropped their target price on Qiagen from $40.00 to $33.00 and set a neutral rating for the company in a report on Tuesday. Goldman Sachs Group restated a buy rating on shares of Qiagen in a report on Thursday, August 1st. Finally, BNP Paribas upgraded Qiagen from a neutral rating to an outperform rating in a report on Friday, July 12th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company. The company has a consensus rating of Hold and an average target price of $36.88.

Shares of Qiagen stock traded up $0.91 during trading on Wednesday, hitting $27.26. 36,237 shares of the stock traded hands, compared to its average volume of 1,115,450. The company has a quick ratio of 1.59, a current ratio of 1.77 and a debt-to-equity ratio of 0.54. The stock has a market cap of $7.23 billion, a price-to-earnings ratio of 20.16, a PEG ratio of 2.09 and a beta of 0.85. The firm’s fifty day moving average is $33.41 and its 200-day moving average is $37.48. Qiagen has a 52 week low of $25.04 and a 52 week high of $41.55.



Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Wednesday, July 24th. The company reported $0.33 EPS for the quarter, missing the consensus estimate of $0.34 by ($0.01). The firm had revenue of $381.60 million for the quarter, compared to the consensus estimate of $386.37 million. Qiagen had a net margin of 12.94% and a return on equity of 12.10%. Qiagen’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.33 earnings per share. On average, analysts forecast that Qiagen will post 1.39 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QGEN. First Trust Advisors LP raised its position in shares of Qiagen by 6.8% in the 1st quarter. First Trust Advisors LP now owns 2,685,140 shares of the company’s stock worth $109,231,000 after acquiring an additional 169,926 shares in the last quarter. O Shaughnessy Asset Management LLC bought a new position in shares of Qiagen in the 1st quarter worth approximately $30,000. Xact Kapitalforvaltning AB bought a new position in shares of Qiagen in the 1st quarter worth approximately $655,000. Rockefeller Capital Management L.P. raised its position in shares of Qiagen by 83.1% in the 1st quarter. Rockefeller Capital Management L.P. now owns 2,113 shares of the company’s stock worth $86,000 after acquiring an additional 959 shares in the last quarter. Finally, AlphaCrest Capital Management LLC bought a new position in shares of Qiagen in the 1st quarter worth approximately $276,000. Institutional investors and hedge funds own 62.10% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Further Reading: Straddles

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.